Metraipolis › archive › dc_68cb0026d39d

Adam Halberstadt — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Adam_Halberstadt
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-07T12:49:17.537Z
SHA-256 of the archived text
524172ebe7c8c548646a073f4ae4294045c7d897781b05b88a351c478f2ea6b6
Stable URL of this page
https://metraipolis.com/documento/dc_68cb0026d39d

How to cite

Adam Halberstadt — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Adam_Halberstadt (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_68cb0026d39d (Metraipolis archive dc_68cb0026d39d, sha256 524172ebe7c8c548646a073f4ae4294045c7d897781b05b88a351c478f2ea6b6)
BibTeX
@misc{dc68cb0026d39d,
  title = {Adam Halberstadt — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Adam_Halberstadt},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_68cb0026d39d; sha256 524172ebe7c8c548646a073f4ae4294045c7d897781b05b88a351c478f2ea6b6},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Adam_Halberstadt. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Adam L. Halberstadt is an American neuroscientist and pharmacologist who studies psychedelic drugs from a cross-species translational perspective. He is a Professor at the University of California, San Diego (UCSD) and the Director of the UCSD Center for Psychedelic Research. One of his most notable contributions has been the development of an automated assay for the head-twitch response, a behavioral proxy of psychedelic effects in animals. He has used the head-twitch response assay to investigate the 5-HT2A receptor signaling mechanisms involved in the effects of psychedelic drugs. He is one of the Principal Investigators on a clinical trial being conducted at UCSD to test whether psilocybin can relieve phantom limb pain in amputees. In February 2021, he formed a collaboration with COMPASS Pathways to develop novel psychedelic drugs as therapeutics. In 2022, has was listed as an inventor on an application for a US Patent covering novel 5-HT2A ligands acting as partial or biased agonists. He has also collaborated with BetterLife Pharma Inc. on a project designed to investigate the pharmacology of the non-psychedelic LSD derivative BOL-148, also known as 2-bromo-LSD. Halberstadt received his bachelor's degree in neuroscience from the University of Delaware in 1998 and his Doctor of Philosophy in neurobiology from the University of Pittsburgh in 2006.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Adam Halberstadt» — https://en.wikipedia.org/wiki/Adam_Halberstadt
Wikidata Q91790020: «researcher (ORCID [numero omesso])» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q91790020
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Adam_Halberstadt?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1372368965, consultata il 2026-11-07T12:44:17.729Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 460fa204501659c35d7a5dc4e060038a6e72e084678a4abf79ffce61256f5157